The report titled ‘Erythropoietin Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019’ features an in-depth analysis of the commercial scope of erythropoietin – a glycoprotein hormone. This report establishes and analyzes the size and scope of the global market for erythropoietin, to offer an accurate estimate of industry size, growth figures and industry trends. The executive summary of the report offers a bird’s eye view of the entire erythropoietin market and the preceding chapters offer a segment-wise analysis.
Future Industrial Analysis of Erythropoietin is available at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1856
The report is unique in that it factors in key recent developments and industry trends to identify factors that will fuel growth in the future, as well as those that will inhibit growth. The report offers a well-balanced view of the global erythropoietin market, making it a valuable investment for companies in the healthcare domain, research institutes, academic institutes, as well as pharmaceutical companies. Furthermore, the company profiles segment features a detailed analysis of all leading market players and their industry standing. This section of the market research report helps you gain an understanding of the competitive landscape and plan your strategies accordingly. Other highlights of the report are: a value chain analysis, Porter’s five forces model analysis, growth drivers and restraints in the market.
Erythropoietin can be classified as a glycoprotein hormone secreted by the body for controlling the production of red blood cells. This hormone is produced in the kidneys, and the cells of this organ that produce erythropoietin, are sensitive to the level of oxygen in the blood. A dip in the blood oxygen levels triggers the cells to produce and release erythropoietin, which in turn stimulates the bone marrow so as to cause the production of oxygen-carrying red blood cells. This process helps maintain an optimal level of oxygen in the human body. The normal erythropoietin range in our body is 4 – 24 mU/ml.
Any abnormality in the levels of this glycoprotein hormone in our blood can be detected via erythropoietin tests. A confirmed abnormality in levels of erythropoietin could potentially be an indication of kidney diseases or a bone marrow disorder. Erythropoietin is being by medical practitioners to counter anemic conditions in the body by stimulating the production of red blood cells. A growing incidence of anemia worldwide – especially as a side effect of chemotherapy and kidney disorders – is boosting the global market for erythropoietin. The scenario in the developed world is, however, different as countries here have reached saturation. This factor will restrain the growth of erythropoietin at the global level to some extent.
It is also possible to produce erythropoietin synthetically, by using a technology known as DNA recombinant.
The market for synthetic erythropoietin market can be categorized as follows:
On the basis of application, the erythropoietin market can be further segmented as:
> Oncology diseases
> End stage renal disease (ESRD)
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453